drugset / Trial / NCT03713190
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
RandomizedSingle-groupDouble-blindTreatment
Summary
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
Timeline
- Start
- 2018-09-10
- Primary completion
- 2020-02-15
- Completion
- 2020-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | — | — |